Skip to main content
CriticalFDAfda-F-3368-2017UNDECLARED ALLERGEN

Metabo-Plus, Garlic/Papaya Plus, No. 103, 90 Capsules, Dietary Supplement

⚠ Critical Alert — Stop Using Immediately

This product has been flagged with severe risks (undeclared allergen). Stop using it now and contact the brand or FDA for a refund, repair, or replacement.

Category
Units Affected
254
Recall Date
July 26, 2017
Issuing Agency
Hazard
Undeclared Allergen

FDA Recall Notice

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-3368-2017.

Undeclared allergens: milk (Whey)

Corrective Action (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-3368-2017.

Recall terminated by FDA.

✅ What you should do

  1. Stop using the product if you own it.
  2. Check the model number, lot code, or sell-by date against the recall notice above.
  3. Contact Natureall-stf Holding, Llc or the retailer where you bought it for a refund, replacement, or repair.
  4. For the most current official instructions, visit the FDA recall page.
  5. If you've been hurt by this product, report the incident to FDA.

Consumer Contact (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-3368-2017.

NatureAll-STF Holding, LLC

FDA

About the U.S. Food and Drug Administration

The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.

Visit FDA.gov →

📣 Report a food, supplement, or cosmetic problem to the FDA

If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.

How to report to FDAFile a report at FDA

Natureall-stf Holding, Llc Recall FAQ

Natureall-stf Holding, Llc is the subject of a supplements safety report: Metabo-Plus, Garlic/Papaya Plus, No. 103, 90 Capsules, Dietary Supplement. The notice was published on July 26, 2017 by the U.S. Food and Drug Administration (FDA). Approximately 254 units are potentially affected.